MD Anderson
Myriad Genetics, MD Anderson Partner to Study Clinical Utility of MRD Assay
Under the five-year agreement, the partners will assess the clinical utility of Myriad's Precise MRD test in breast, gastrointestinal, genitourinary, and gynecological cancers.
In Brief This Week: MD Anderson, Genascence, Seattle Children's Hospital, Abeona, Mount Sinai
News items for the week of Nov. 11, 2024.
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
MD Anderson, Summit Therapeutics to Jointly Study Ivonescimab
The partners inked a five-year deal to study the PD-1/VEGF bispecific antibody across multiple tumor types, including in biomarker-defined indications.
Although the PETRA trial didn't test saruparib against marketed PARP inhibitors, researchers see promising signs that the agent has a better toxicity profile.
May 18, 2023